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Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder that accounts for 
nearly 70% of the more than 50 million dementia cases estimated worldwide. 
There is no cure for AD. Currently, AD diagnosis is carried out using neuropsycho-
logical tests, neuroimaging scans, and laboratory tests. In the early stages of AD, 
brain computed tomography (CT) and magnetic resonance imaging (MRI) find-
ings may be normal, but in late periods, diffuse cortical atrophy can be detected 
more prominently in the temporal and frontal regions. Electroencephalogram 
(EEG) is a test that records the electrical signals of the brain by using electrodes 
that directly reflects cortical neuronal functioning. In addition, EEG is noninva-
sive and widely available at low cost, has high resolution, and provides access to 
neuronal signals, unlike functional MR or PET which indirectly detects metabolic 
signals. Accurate, specific, and cost-effective biomarkers are needed to track the 
early diagnosis, progression, and treatment response of AD. The findings of EEG 
in AD are now identified as biomarkers. In this chapter, we reviewed studies that 
used EEG or event-related potential (ERP) indices as a biomarker of AD.
Keywords: Alzheimer’s disease, biomarker, EEG, quantitative EEG, 
neurodegeneration
1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease that accounts for about 
70% of the estimated 46 million dementia cases worldwide. Although there is no 
definitive treatment for AD, early diagnosis and correct follow-up to stop disease 
progression can improve the quality of life for the AD patients and caregivers [1].
Amnesia, aphasia, apraxia, and agnosia are the leading clinical signs of AD. 
The first symptom in AD is often the loss of the ability to learn new information 
(amnesia). Loss of episodic memory is the main symptom of AD. Episodic memory 
is particularly concerned with the hippocampus. In the beginning, the patient 
becomes forgetful, repeats the same things, and loses his things. Semantic memory 
is about social events and general knowledge. It is not destroyed as markedly as 
episodic memory in the early stages of AD. As the disease progresses, destruction 
starts in semantic memory [2–4].
According to the symptomatology, AD is divided into three stages: (1) preclinical, 
(2) mild cognitive impairment (MCI), and (3) AD-related dementia. (1) Preclinical 
AD: changes in brain, blood, and cerebrospinal fluid associated with AD begin 
to occur, but the patient does not show any symptoms. This stage may start years 
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or decades before the first clinical symptoms of dementia [5]. (2) Mild cognitive 
impairment (MCI): MCI describes the clinical situation between normal aging 
and Alzheimer’s disease. In 1999, the information that memory impairment differs 
according to age, as well as educational level, was added to the definition made on 
MCI. MCI usually manifests itself with subjective complaints such as forgetting the 
names and not being able to remember where the items were placed. However, it has 
been observed that 30% of cases diagnosed with MCI do not progress to AD soon 
[6]. (3) Alzheimer’s dementia: Typically, the symptoms of the disease begin with 
mild memory difficulties and cognitive impairment develops into dysfunctions in 
complex daily activities and some other aspects of cognition. When AD is diagnosed 
clinically, neuron loss and neuropathological lesions occur in many brain regions [7]. 
However, there is no ideal biomarker to identify AD, and a definitive diagnosis can 
only be made by autopsy or biopsy. Therefore, the diagnosis of AD can be made by 
medical history, laboratory tests, neuroimaging, and neuropsychological methods. 
These clinical assessments are not specific and costly. As a result, an accurate, 
universal, specific, and cost-effective biomarker is needed for early diagnosis and to 
monitor disease progression and treatment response [8].
The National Institute on Aging-Alzheimer’s Association (NIA-AA) has devel-
oped new study criteria to use a panel of prognostic fluids and imaging biomarkers 
to determine the probability of AD pathology and preclinical AD staging and 
prodromal and later progression to clinical AD. These are cerebrospinal fluid 
(CSF) amyloid-β (Aβ) 42, amyloid positron emission tomography (PET), CSF 
total tau, threonine 181 (T181) phospho-tau, magnetic resonance imaging (MRI) 
mesial temporal lobe (MTL) atrophy, 18F-fluorodeoxyglucose (FDG)-PET tem-
poroparietal/precuneus hypometabolism, or hypoperfusion [9]. Today, standard 
neuropsychological tests are used to diagnose AD and are widely supported by 
expensive neuroimaging methods and invasive laboratory tests. In recent years, 
electroencephalography (EEG) has emerged as an alternative noninvasive technique 
compared to more expensive neuroimaging methods such as MRI and PET [10, 11].
2. Alzheimer’s disease and its pathophysiology
Data obtained with AD have shown the presence of amyloid plaques and neurofi-
brillary tangles in the pathology of the disease and that these pathological aggregates 
have a specific distribution pattern and density [12, 13].
Molecular studies have shown that the main component of amyloid plaques is 
amyloid beta (Aβ), and neurofibrillary tangles are tau protein. In AD patients, the 
pathway that forms the Aβ peptide is more active or is thought to be a defect in the 
mechanism of Aβ clearance. There are mature fibrils in the structure of amyloid 
plaques. In pathology studies in AD patients, amyloid plaques are indispensable 
pathological findings and Aβ formation in the pathogenesis of the disease is thought 
to initiate the pathogenesis of the disease. This hypothesis is defined as the “amyloid 
cascade hypothesis” [14]. In the pathogenesis of AD, tau hyperphosphorylation is 
known to impair microtubule stability and function, as well as to gain toxic func-
tion, for instance, tau aggregates induce apoptosis. However, like Aβ, it is thought 
that the tau oligomers they form are associated with neurodegeneration and 
memory impairment rather than the aggregates formed by the tau protein [15].
3. Alzheimer’s disease and EEG
The source of routine EEG activity recorded from the scalp is the postsynaptic 
potentials of cortical pyramidal cells. According to the synaptic activity being 
3
EEG Biomarker for Alzheimer’s Disease
DOI: http://dx.doi.org/10.5772/intechopen.93711
excitatory and inhibitory, the postsynaptic membrane becomes depolarized or 
hyperpolarized. The total electrical current generated by these excitatory and 
inhibitory postsynaptic potentials from millions of neurons creates superficial 
EEG activity. Adeli and Ghosh-Dastidar developed the wavelet-chaos method for 
the analysis of delta, theta, alpha, and beta (Table 1) subbands of EEG to identify 
potential markers in Alzheimer’s disease.
To evaluate the effect of visual warning and attention, evaluation is done with 
eyes open and eyes closed. EEGs from different loci in the brain are used to explore 
the responsible areas of the brain and directly measure the functioning of synapses 
in real time [16, 17].
In AD, a significant decrease in cortical alpha frequency (8–10.5 Hz) was 
observed, especially in the limbic, temporal, parietal, and central areas [6]. 
However, it has been reported that the age of onset of AD can change this criterion, 
and that focal and diffuse EEG abnormalities are more common in early onset AD 
patients than in late-age AD patients. In the first studies, an increase in theta activity 
in EEG was considered as one of the earliest changes in Alzheimer’s dementia, while 
alpha activity was found to decrease during or after the disease [18].
EEG markers showing the progression of the disease in MCI cases include an 
increase in delta and theta power and a decrease in beta or alpha power in the tem-
poral and occipital regions [19]. Osipova et al. showed that alpha rhythm shifts from 
the parieto-occipital region to temporal regions in AD [20]. In other spontaneous 
EEG studies, it was found that frontal delta and occipital theta sources were higher 
in MCI patients than healthy ones, and frontal delta sources and the Mini-Mental 
State Examination (MMSE) showed negative correlations [21, 22].
The cortical cholinergic system has an important role in controlling many 
different functions such as cerebral blood flow, cortical activity, sleep/wake 
cycle, modulation of cortical plasticity, and cognitive performance and learning-
memory processes. The presence of cholinergic neurons in the basal forebrain 
was first reported by Shute and Lewis in 1967. ACh deficiency is observed in the 
brains of individuals with AD in the entire cortex, especially the temporoparietal 
cortex [23, 24]. Also, one of the possible mechanisms underlying the observed 
relationship between Aβ42 and increased slow EEG activity is Aβ and cholinergic 
deficiencies in the brain in AD. Cholinergic therapy has different effects on delta 
and theta oscillation responses. Theta oscillations were similar in controls to 
those receiving cholinergic therapy in the AD patients, regardless of treatment. In 
other words, theta oscillation responses are affected by cholinergic therapy in AD 
patients, while the amplitudes of delta oscillation responses are not affected by 
cholinergic therapy [25].
Moreover, in studies evaluating the relationship between AD neuropathology, 
EEG frequencies, and CSF markers, amyloid β42 (Aβ42) showed a significant 
relationship with slow frequency (delta and theta) activity, while phospho-tau 
(p-tau) and total tau (t-tau) are associated with activity at only fast frequencies 
(alpha and beta) (26). Smailovic et al. demonstrated the correlation of qEEG and 
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CSF abnormalities with the AD profile at different stages of cognitive impairment, 
which revealed that qEEG can demonstrate neurodegeneration-induced synaptic 
dysfunction [26].
4. Sensory-stimulated oscillations
Sensory-evoked oscillatory responses are obtained by digital filtering of the 
frequency bands such as delta, theta, alpha, beta, and gamma of the “evoked 
potential” that appears with the delivery of the sensory stimulus. Haupt et al. 
showed that gamma and beta2 bands showed a different distribution compared to 
both patient groups in the visual-evoked oscillatory responses that they examined 
in Alzheimer’s, MCI and healthy group controls, and the current density distribu-
tion followed a movement from the right hemisphere to the left hemisphere in these 
patient groups. In a visual sensory-evoked oscillatory study, the difference between 
AD patients and the healthy group was shown to disappear when the stimulus 
did not contain the cognitive load. Besides, when controlled, the parieto-occipital 
theta-stimulated oscillatory responses of the untreated Alzheimer’s patient group 
were found to be higher than those of the treated Alzheimer’s patient group and the 
healthy group [27].
5. Sensory-evoked coherencies and event-related coherences
Coherence or phase-locking statistics are the most common methods used to 
evaluate relationships between neural communities [28, 29]. Hogan et al. inves-
tigated memory-related EEG strength and coherence in the temporal and central 
areas in early stage AD patients and the normal control group and the behavioral 
performances of mild Alzheimer patients did not differ significantly from the 
healthy ones while they found a decrease in high alpha coherence between central 
and right temporal cortex of Alzheimer patients [30]. Rossini et al. measured the 
spontaneous EEG coherence of healthy control and MCI patients (progressive and 
constant) and found that the course of disease in patients with high coherence 
in the delta and gamma frequency bands progressed faster [31]. In another study 
examining the coherencies related to the event in patients with mild AD using 
visual sparse stimuli, the authors found higher OI coherence in the “delta,” “theta,” 
and “alpha” bands compared to the controls in the AD group that did not receive 
drug treatment. Alpha OI coherence values are higher in the medicated group 
compared to the drug-free AD group [32].
6. Conclusion
AD is a progressive neurocognitive disease in the elderly population. This disease 
is characterized by behavioral problems, cognitive impairment, delirium, and 
memory loss.
Most studies in AD have been done on frequency changes with EEG reactivity. 
When eyes are open, theta and alpha reactivity index and alpha/theta index were 
integrated into this study and were found as a useful approach to evaluate quantita-
tive EEG (qEEG). EEG is advantageous compared to functional MRI or PET, which 
indirectly detects metabolic signals due to its noninvasive, wide availability, low 
cost, and direct access to neuronal signaling. Studies reveal that neuritic plaques, 
nodes, tangles, granulovacuolar degeneration, and the formation of amyloid 
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angiopathy are some of the pathological variations that cause AD. Neuroprotective 
and symptomatic approaches such as antioxidants and neurotransmitters are 
effective in treating AD symptoms and delay their development. No cure can treat 
AD, but medications that can treat disease symptoms and delay its progression have 
been developed and will continue to be developed. Therefore, early diagnosis is the 
key in treating the disease. Advances in neuroimaging technology, cognitive neuro-
science, psychopathology, neuropathology, and neurobiology lead to the discovery 
of AD biomarkers for early detection.
Researchers are also working on improving the accuracy of EEG-based AD 
diagnosis. New studies are needed to develop an algorithm in the early onset 
diagnosis of AD, and this will happen sometime in the future.
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